Publish time: 2021-11-18 00:00:00
28A-1101026
2021-11-18
RU 2826172、MY MY-204510-A、US provisional
Development of mRNA vaccine has emerged as an effective and speedy strategy to control the spread of new pathogens. Here, we found that the mRNA vaccine of SARS-CoV-2 spike protein with mutation of glycosites to expose more conserved regions elicited antibodies with broader protection against the alpha, beta, gamma and delta variants, and induced a stronger CD8+ T cell response against the wild-type and variants of concern as compared to the unmodified mRNA. Our finding provides a new kind of broad-spectrum SARS-CoV-2 mRNA vaccines.
Compared to other SARS-CoV-2 vaccines, our vaccine provides faster, safer and cheaper mass production, and also provides better protection against infections of SARS-CoV-2 and its variants of concern.
A broadly protective SARS-CoV-2 spike protein mRNA vaccine against the wild-type and variants of concern.
Chi-Huey Wong, Ching-Yi Wu, and Che Ma
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Broad-spectrum SARS-CoV-2 mRNA vaccine